Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Monotherapy in Active Rheumatoid Arthritis
NCT00771251Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2008
- Primary completion
- Oct 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of golimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR 20% Response at 14 weeks. Started May 2008; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00771251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771251.